Allogene Therapeutics, Inc. Revenue
Allogene Therapeutics, Inc. (ALLO) reported Revenue of $4.64 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-12
- Allogene Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-06-30 was $4.64M.
- Allogene Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $0.00.
- Allogene Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $0.00.
- Allogene Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $0.00.
- Allogene Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Allogene Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $22.00K, a 76.84% decline from fiscal 2023.
- Allogene Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $95.00K, a 39.10% decline from fiscal 2022.
- Allogene Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $156.00K, a 99.86% decline from fiscal 2021.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 3 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month as first filed | Revenue from Contract with Customer, Excluding Assessed Tax 12 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.64M 10-Q · filed 2026-08-12 | $4.64M 10-Q · filed 2026-08-12 | ||||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $0.00 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 | ||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $22.00K 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $0.00 10-Q · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $22.00K 10-Q · filed 2025-11-06 | $43.00K derived: sum of 4 quarters · filed 2025-11-06 | ||||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | $22.00K 10-Q · filed 2025-08-13 | $43.00K derived: sum of 3 quarters · filed 2025-08-13 | $65.00K derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $22.00K 10-Q · filed 2025-05-13 | $43.00K derived: sum of 2 quarters · filed 2025-05-13 | $65.00K derived: sum of 3 quarters · filed 2025-05-13 | $87.00K derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $43.00K derived: sum of 2 quarters · filed 2025-03-13 | $65.00K derived: sum of 3 quarters · filed 2025-03-13 | $95.00K 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | $22.00K 10-Q · filed 2024-11-07 | $43.00K 10-Q · filed 2023-11-02 | $44.00K derived: sum of 2 quarters · filed 2024-11-07 | $74.00K 10-Q · filed 2024-11-07 | $139.00K 10-Q · filed 2023-11-02 | $100.00K derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | $22.00K 10-Q · filed 2024-08-07 | $44.00K 10-Q · filed 2023-08-02 | $52.00K 10-Q · filed 2024-08-07 | $96.00K 10-Q · filed 2023-08-02 | $78.00K derived: sum of 3 quarters · filed 2024-08-07 | $105.00K derived: sum of 4 quarters · filed 2024-08-07 | ||
| 2023-03-31 | $30.00K 10-Q · filed 2024-05-13 | $52.00K 10-Q · filed 2023-05-03 | $56.00K derived: sum of 2 quarters · filed 2024-05-13 | $83.00K derived: sum of 3 quarters · filed 2024-05-13 | $147.00K derived: sum of 4 quarters · filed 2024-05-13 | |||
| 2022-12-31 | $26.00K derived: 10-K/A 12 month − 10-K 9 month · filed 2024-03-14 | $53.00K derived: sum of 2 quarters · filed 2024-03-14 | $117.00K derived: sum of 3 quarters · filed 2024-03-14 | $156.00K 10-K/A · filed 2024-03-14 | $243.00K 10-K · filed 2023-02-28 | |||
| 2022-09-30 | $27.00K 10-K · filed 2024-03-14 | $49.00K 10-Q · filed 2022-11-02 | $91.00K derived: sum of 2 quarters · filed 2024-03-14 | $130.00K 10-K · filed 2024-03-14 | $196.00K 10-Q · filed 2022-11-02 | $75.78M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-06-30 | $64.00K 10-K · filed 2024-03-14 | $86.00K 10-Q · filed 2022-08-09 | $103.00K 10-K · filed 2024-03-14 | $147.00K 10-Q · filed 2022-08-09 | $75.75M derived: sum of 3 quarters · filed 2024-03-14 | $75.80M derived: sum of 4 quarters · filed 2024-03-14 | ||
| 2022-03-31 | $39.00K 10-K · filed 2024-03-14 | $61.00K 10-Q · filed 2022-05-04 | $75.69M derived: sum of 2 quarters · filed 2024-03-14 | $75.74M derived: sum of 3 quarters · filed 2024-03-14 | $75.78M derived: sum of 4 quarters · filed 2024-03-14 | |||
| 2021-12-31 | $75.65M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $75.70M derived: sum of 2 quarters · filed 2024-03-14 | $75.74M derived: sum of 3 quarters · filed 2024-03-14 | $114.09M 10-K/A · filed 2024-03-14 | $38.49M 10-K · filed 2022-02-23 | |||
| 2021-09-30 | $49.00K 10-Q · filed 2022-11-02 | $93.00K derived: sum of 2 quarters · filed 2022-11-02 | $38.44M 10-Q · filed 2022-11-02 | $38.44M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-06-30 | $44.00K 10-Q · filed 2022-08-09 | $38.39M 10-Q · filed 2022-08-09 | $38.39M derived: sum of 3 quarters · filed 2024-03-14 | $38.39M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2021-03-31 | $38.34M 10-Q · filed 2022-05-04 | $38.34M derived: sum of 2 quarters · filed 2024-03-14 | $38.34M derived: sum of 3 quarters · filed 2024-03-14 | $38.34M derived: sum of 4 quarters · filed 2024-03-14 | ||||
| 2020-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $0.00 10-K/A · filed 2024-03-14 | ||||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | ||||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-05 | |||||||
| 2019-12-31 | $0.00 10-K · filed 2022-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |